ACTU Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 22.50 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

20.00

Averages

22.50

High

25.00

Current: 0.000

Low

20.00

Averages

22.50

High

25.00

B. Riley

NULL -> Buy

initiated

$20

2025-08-26

Reason

B. Riley

Price Target

$20

2025-08-26

initiated

NULL -> Buy

Reason

B. Riley initiated coverage of Actuate Therapeutics with a Buy rating and $20 price target. The firm views the company's lead asset elraglusib as a "transformative" advancement in pancreatic ductal adenocarcinoma treatment. In a Phase 2 study, elraglusib delivered an "unprecedented" survival benefit in the front-line setting with a 37% reduction in death risk that remained consistent in more aggressive disease characterized by the presence of liver metastasis, the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Initiates

$20

2025-03-17

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$20

2025-03-17

Initiates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Actuate Therapeutics Inc (ACTU.O) is -6.35, compared to its 5-year average forward P/E of -0.68. For a more detailed relative valuation and DCF analysis to assess Actuate Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.68

Current PE

-6.35

Overvalued PE

1.42

Undervalued PE

-2.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACTU News & Events

Events Timeline

No data

News

9.0

2025-12-15NASDAQ.COM

Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers

4.0

2025-09-23Benzinga

HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact

8.5

2025-09-10Newsfilter

Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering

People Also Watch

Frequently Asked Questions

What is Actuate Therapeutics Inc (ACTU) stock price today?

The current price of ACTU is 6.14 USD — it has decreased -2.23 % in the last trading day.

What is Actuate Therapeutics Inc (ACTU)'s business?

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

What is the price predicton of ACTU Stock?

What is Actuate Therapeutics Inc (ACTU)'s revenue for the last quarter?

Actuate Therapeutics Inc revenue for the last quarter amounts to -5.47M USD, increased 1.47 % YoY.

What is Actuate Therapeutics Inc (ACTU)'s earnings per share (EPS) for the last quarter?

Actuate Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Actuate Therapeutics Inc (ACTU)'s fundamentals?

The market is revising No Change the revenue expectations for Actuate Therapeutics, Inc. (ACTU) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -24.10%.

How many employees does Actuate Therapeutics Inc (ACTU). have?

Actuate Therapeutics Inc (ACTU) has 10 emplpoyees as of January 10 2026.

What is Actuate Therapeutics Inc (ACTU) market cap?

Today ACTU has the market capitalization of 142.71M USD.